戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ; also known as Jo-1) in the pathogenesis of idiopathic inflammatory myopathy.
2  muscle inflammation that is the hallmark of idiopathic inflammatory myopathy.
3 d be undertaken in any patient with presumed idiopathic inflammatory myopathy.
4 was first identified in 1997 as a subtype of idiopathic inflammatory myopathy.
5 hematosus, systemic sclerosis, vasculitis or idiopathic inflammatory myopathies.
6 ate immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies.
7 the optimal design of clinical trials in the idiopathic inflammatory myopathies.
8  the development of better therapies for the idiopathic inflammatory myopathies.
9 ggest that non-immunological factors promote idiopathic inflammatory myopathies.
10 mune responses and clinical syndromes in the idiopathic inflammatory myopathies.
11 ting the serial CMAS scores of children with idiopathic inflammatory myopathies.
12 sorders than the currently used designation, idiopathic inflammatory myopathies.
13 skeletal muscle involvement in patients with idiopathic inflammatory myopathies.
14 s of strength and endurance in children with idiopathic inflammatory myopathies.
15 re and refining prognostic stratification in idiopathic inflammatory myopathies.
16 whereas it was rarely seen in those of other idiopathic inflammatory myopathies.
17 gents that hold promise for the treatment of idiopathic inflammatory myopathies.
18 whereas others are distinct from adult-onset idiopathic inflammatory myopathies.
19 es (MSAs) have become pivotal biomarkers for idiopathic inflammatory myopathies and have revolutioniz
20 assessing disease activity and damage in the idiopathic inflammatory myopathies and speculates on pos
21                  The association between the idiopathic inflammatory myopathies and the development o
22                Inclusion body myositis is an idiopathic inflammatory myopathy and the most common myo
23        In this large series of patients with idiopathic inflammatory myopathy, anti-Jo-1 antibody lev
24                                              Idiopathic inflammatory myopathies are a group of immune
25                                          The idiopathic inflammatory myopathies are an important and
26                                          The idiopathic inflammatory myopathies are diseases that can
27     Inasmuch as the clinical features of the idiopathic inflammatory myopathies are not easily differ
28 eurin inhibitors are being used to treat the idiopathic inflammatory myopathies, but their efficacy h
29 teroviruses as potential etiologic agents of idiopathic inflammatory myopathy, but their relationship
30                  Diseases that may mimic the idiopathic inflammatory myopathies can be differentiated
31                                              Idiopathic inflammatory myopathies can significantly imp
32 ing myopathy (IMNM) is considered one of the idiopathic inflammatory myopathies, comprising dermatomy
33  the pathogenesis and course of the juvenile idiopathic inflammatory myopathies continued this year.
34 dermatomyositis, polymyositis, and the other idiopathic inflammatory myopathies focus primarily on fe
35 nces in the development of therapies for the idiopathic inflammatory myopathies have been enabled by
36          New classification criteria for the idiopathic inflammatory myopathies have been proposed in
37 tions into possible infectious causes of the idiopathic inflammatory myopathies have focused on retro
38 our understanding of the pathogenesis of the idiopathic inflammatory myopathies have served to identi
39                                          The idiopathic inflammatory myopathies (IIM) continue to pro
40  the case for other autoimmune diseases, the idiopathic inflammatory myopathies (IIM) develop as a re
41                                              Idiopathic inflammatory myopathies (IIM) involve chronic
42                                              Idiopathic inflammatory myopathies (IIM), also known as
43 f patients with systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), and HLA-DQA1*0
44 ease damage, have not been developed for the idiopathic inflammatory myopathies (IIM), thus limiting
45 ry remain significant clinical challenges in idiopathic inflammatory myopathies (IIM).
46 rovement in clinical trials of patients with idiopathic inflammatory myopathy (IIM) has varied to dat
47                                  Adult-onset idiopathic inflammatory myopathy (IIM) is associated wit
48                 The sequelae associated with idiopathic inflammatory myopathy (IIM) often result in d
49 date the reader on immunogenetic advances in idiopathic inflammatory myopathy (IIM) over the past 18
50 ) and North American Caucasian patients with idiopathic inflammatory myopathy (IIM).
51 with myositis but without silicone implants (idiopathic inflammatory myopathy; IIM patients).
52                                          The idiopathic inflammatory myopathies (IIMs) are a heteroge
53                                              Idiopathic inflammatory myopathies (IIMs) are severe aut
54       Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoim
55 Mechanisms driving the autoimmune process in idiopathic inflammatory myopathies (IIMs) have not been
56 en made in understanding the genetics of the idiopathic inflammatory myopathies (IIMs) in the past 2
57        Increasing evidence suggests that the idiopathic inflammatory myopathies (IIMs) result from ce
58                     This update on childhood idiopathic inflammatory myopathies (IIMs) reviews recent
59                                              Idiopathic inflammatory myopathies (IIMs), or myositis,
60 y contribute to the etiology of the juvenile idiopathic inflammatory myopathies (IIMs), which are sys
61 ns of birth dates in groups of patients with idiopathic inflammatory myopathies (IIMs).
62 rable remissions in patients with refractory idiopathic inflammatory myopathies (IIMs).
63 le dermatomyositis is the most common of the idiopathic inflammatory myopathies in children.
64 most striking humoral characteristics of the idiopathic inflammatory myopathies is the specific targe
65              The childhood-onset or juvenile idiopathic inflammatory myopathies (JIIMs) are a heterog
66 to advance our understanding of the juvenile idiopathic inflammatory myopathies (JIIMs).
67 py has shown the ability to diagnose several idiopathic inflammatory myopathy mimics.
68                                Patients with idiopathic inflammatory myopathies need to be managed in
69 evere autoimmune disease and the most common idiopathic inflammatory myopathy of children.
70                                          The idiopathic inflammatory myopathies or myositis syndromes
71        Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndrome
72 Advances in dermatomyositis and the juvenile idiopathic inflammatory myopathies over the past year in
73 ome to the forefront in evaluating difficult idiopathic inflammatory myopathy patients.
74 neutrophils in systemic lupus erythematosus, idiopathic inflammatory myopathies, psoriasis, hidradeni
75                    In patients with juvenile idiopathic inflammatory myopathy, stair-stepping exercis
76 es should be distinguished from the commoner idiopathic inflammatory myopathies such as polymyositis
77 ases including systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, ne
78 ve assessments of therapeutic strategies for idiopathic inflammatory myopathies were recently publish
79  were performed in 19 patients with juvenile idiopathic inflammatory myopathy who performed stair-ste
80   Methods for assessing target organs of the idiopathic inflammatory myopathies will likely evolve as
81                Dermatomyositis is one of the idiopathic inflammatory myopathies with characteristic c
82 poradic inclusion body myositis (sIBM) is an idiopathic inflammatory myopathy with invasion of CD8 T